Cite

HARVARD Citation

    Liang, S. et al. (2016). Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharmaceutical development and technology. pp. 121-126. [Online]. 
  
Back to record